Trial Profile
A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Clovis Oncology [CEASED]
- 01 Aug 2023 Planned End Date changed from 1 May 2024 to 25 Jul 2024.
- 01 Aug 2023 Planned primary completion date changed from 1 May 2024 to 25 Jul 2024.
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.